Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research Article

Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Intrahepatic cholangiocarcinomas (ICC) are relatively rare malignant tumors associated with a poor prognosis. Recent studies using genome-wide sequencing technologies have mainly focused on identifying new driver mutations. There is nevertheless a need to investigate the spectrum of copy number aberrations in order to identify potential target genes in the altered chromosomal regions. The aim of this study was to characterize the patterns of chromosomal copy-number alterations (CNAs) in ICC.

Methods

53 patients having ICC with frozen material were selected. In 47 cases, DNA hybridization has been performed on a genomewide SNP array. A procedure with a segmentation step and a calling step classified genomic regions into copy-number aberration states. We identified the exclusively amplified and deleted recurrent genomic areas. These areas are those showing the highest estimated propensity level for copy loss (resp. copy gain) together with the lowest level for copy gain (resp. copy loss). We investigated ICC clustering. We analyzed the relationships between CNAs and clinico-pathological characteristics.

Results

The overall genomic profile of ICC showed many alterations with higher rates for the deletions. Exclusively deleted genomic areas were 1p, 3p and 14q. The main exclusively amplified genomic areas were 1q, 7p, 7q and 8q. Based on the exclusively deleted/amplified genomic areas, a clustering analysis identified three tumors groups: the first group characterized by copy loss of 1p and copy gain of 7p, the second group characterized by 1p and 3p copy losses without 7p copy gain, the last group characterized mainly by very few CNAs. From univariate analyses, the number of tumors, the size of the largest tumor and the stage were significantly associated with shorter time recurrence. We found no relationship between the number of altered cytobands or tumor groups and time to recurrence.

Conclusion

This study describes the spectrum of chromosomal aberrations across the whole genome. Some of the recurrent exclusive CNAs harbor candidate target genes. Despite the absence of correlation between CNAs and clinico-pathological characteristics, the co-occurence of 7p gain and 1p loss in a subgroup of patients may suggest a differential activation of EGFR and its downstream pathways, which may have a potential effect on targeted therapies.
Literature
1.
Nakanuma Y, Curado M, Franceschi S, Gores G, Paradis V, Sripa B. Intrahepatic cholangiocarcinoma In: Bosman FT, HR Carneiro F, ND T, editors. WHO Classification of the Tumours of the Digestive System, vol. 2. 2nd edn. Lyon: IARC press: 2010. p. 217–24.
2.
Shaib Y, Davila J, McGlynn K, El-Serag H. Rising incidence of intrahepatic cholangiocarcinoma in the united states: a true increase?J Hepatol. 2004; 40:472–7.CrossRefPubMed
3.
Chang K, Chang J, Yen Y. Increasing incidence of intra-hepatic cholangiocarcinoma and its relationship to chronic viral hepatitis. J Natl Compr Canc Netw. 2009; 7:423–7.PubMed
4.
Rizvi S, Gores G. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013; 145:1215–29.CrossRefPubMed
5.
Palmer W, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? a meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol. 2012; 57:69–76.CrossRefPubMedPubMedCentral
6.
Cardinale V, Semeraro R, Torrice A, Gatto M, Napoli C, Bragazzi M, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol. 2010; 2:407–16.CrossRefPubMedPubMedCentral
7.
8.
9.
Ohashi K, Tstsumi M, Nakajima Y, Nakano H, Konishi Y. Ki-ras point mutations and proliferation activity in biliary tract carcinomas. Br J Cancer. 1996; 74:930–5.CrossRefPubMedPubMedCentral
10.
Hahn S, Bartsch D, Schroers A, Galehdari H, Becker M, Ramaswamy A, et al. Mutations of the dpc4/smad4 gene in biliary tract carcinoma. Cancer Res. 1998; 58:1124–6.PubMed
11.
Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Köckerling F, Hauss J, et al. Frequency of p16 (ink4a) alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut. 2000; 47:721–7.CrossRefPubMedPubMedCentral
12.
Endo K, Ashida K, Miyake N, Terada T. E-cadherin gene mutations in human intrahepatic cholangiocarcinoma. J Pathol. 2001; 193:310–7.CrossRefPubMed
13.
Taniai M, Higuchi H, Burgart L, Gores G. p16ink4a promoter mutations are frequent in primary sclerosing cholangitis (psc) and psc-associated cholangiocarcinoma. Gastroenterology. 2002; 123:1090–8.CrossRefPubMed
14.
Terada T, Nakanuma Y, Sirica A. Immunohistochemical demonstration of met overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol. 1998; 29:175–80.CrossRefPubMed
15.
Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K, et al. The role of overexpression and gene amplification of cyclin d1 in intrahepatic cholangiocarcinoma. J Hepatol. 2001; 35:74–9.CrossRefPubMed
16.
Ukita Y, Kato M, Terada T. Gene amplification and mrna and protein overexpression of c-erbb-2 (her-2/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry. J Hepatol. 2002; 36:780–5.CrossRefPubMed
17.
AE S. Role of erbb family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol. 2008; 14:7033–58.CrossRef
18.
Andersen J, Spe eB, Blechacz B, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012; 142:1021–31.CrossRefPubMed
19.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013; 144:829–40.CrossRefPubMedPubMedCentral
20.
Jiao Y, Pawlik T, Anders R, Selaru F, Streppel M, Lucas D, et al. Exome sequencing identifies frequent inactivating mutations in bap1, arid1a and pbrm1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45:1470–3.CrossRefPubMedPubMedCentral
21.
Borad M, Champion M, Egan J, Liang W, Fonseca R, Bryce A, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in fgfr and egfr pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014; 10:1004135.CrossRef
22.
Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K, et al. Frequent mutation of isocitrate dehydrogenase (idh)1 and idh2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012; 17:72–9.CrossRefPubMed
23.
Kipp B, Voss J, Kerr S, Barr Fritcher E, Graham R, Zhang L, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012; 43:1552–8.CrossRefPubMed
24.
Zhu A, Borger D, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014; 21:3827–34.CrossRefPubMedPubMedCentral
25.
Voss J, Holtegaard L, Kerr S, Fritcher E, Roberts L, Gores G, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol. 2013; 44:1216–22.CrossRefPubMed
26.
Ross J, Wang K, Gay L, Al-Rohil R, Rand J, Jones D, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist. 2014; 19:235–42.CrossRefPubMedPubMedCentral
27.
Ong C, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012; 44:690–3.CrossRefPubMed
28.
Chan-On W, Nairismägi M, Ong C, Lim W, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013; 45:1474–8.CrossRefPubMed
29.
Simbolo M, Fassan M, Ruzzenente A, Mafficini A, LD W, Corbo V, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014; 5:2839–52.CrossRefPubMedPubMedCentral
30.
Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014; 59:1427–34.CrossRefPubMed
31.
Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A. Cancer staging manual. In: AJCC Cancer Staging Manual. 7th edn. New York: Springer: 2009. p. 1–649.
32.
Illumina. http://​www.​illumina.​com/​.
33.
Peiffer D, Le J, Steemers F, Chang W, Jenniges T, Garcia F, et al. High-resolution genomic profiling of chromosomal aberrations using infinium whole-genome genotyping. Genome Res. 2006; 16:1136–48.CrossRefPubMedPubMedCentral
34.
Pierre-Jean M, Rigaill G, Neuvial P. Performance evaluation of dna copy number segmentation methods. Briefings in Bioinf. 2014. in press.
35.
36.
37.
Hartigan J, Hartigan P. The dip test of unimodality. Ann Stat. 1985; 13:70–84.CrossRef
38.
Broet P, Tan P, Alifano M, Camilleri-Broet S, Richardson S. Finding exclusively deleted or amplified genomic areas in lung adenocarcinomas using a novel chromosomal pattern analysis. BMC Med Genomics. 2009; 2:43.CrossRefPubMedPubMedCentral
39.
Toussile W, Gassiat E. Model Based Clustering using multilocus data with loci selection. Adv Data Anal Classification. 2009; 3:109–34.CrossRef
40.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2012. ISBN 3-900051-07-0. http://​www.​R-project.​org/​.
41.
42.
Miller G, Socci N, Dhall D, D’Angelica M, DeMatteo R, Allen P, et al. Genome wide analysis and clinical correlation of chromosomal and transcriptional mutations in cancers of the biliary tract. J Exp Clin Cancer Res. 2009; 12:28–62.
43.
Dachrut S, Banthaisong S, Sripa M, Paeyao A, Ho C, Lee S, et al. Dna copy-number loss on 1p36.1 harboring runx3 with promoter hypermethylation and associated loss of runx3 expression in liver fluke-associated intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev. 2009; 10:575–82.PubMed
44.
45.
Chou A, Toon C, Clarkson A, Sioson L, Houang M, Watson N, et al. Loss of arid1a expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol. 2014; 45(8):1697–703.CrossRefPubMed
46.
Samartzis E, Gutsche K, Dedes K, Fink D, Stucki M, Imesch P. Loss of arid1a expression sensitizes cancer cells to pi3k- and akt-inhibition. Oncotarget. 2014; 5(14):5295–30.CrossRefPubMedPubMedCentral
47.
Hollander M, Maier C, Hobbs E, Ashmore A, Linnoila R, Dennis P. Akt1 deletion prevents lung tumorigenesis by mutant k-ras. Oncogene. 2011; 30:1812–21.CrossRefPubMedPubMedCentral
48.
49.
Leone F, Cavalloni G, Pignochino Y, Sarotto I, Ferraris R, Piacibello W, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006; 12:1680–5.CrossRefPubMed
50.
Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. Prognostic significance of overexpression of c-met oncoprotein in cholangiocarcinoma. Br J Cancer. 2011; 105:131–8.CrossRefPubMedPubMedCentral
Metadata
Title
Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma
Publication date
01-12-2015
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1111-6

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma

Research article

The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma

Research article

Cytokine serum levels during post-transplant adverse events in 61 pediatric patients after hematopoietic stem cell transplantation

Study protocol

Physical Exercise Training versus Relaxation in Allogeneic stem cell transplantation (PETRA Study) – Rationale and design of a randomized trial to evaluate a yearlong exercise intervention on overall survival and side-effects after allogeneic stem cell transplantation

Technical advance

High-recovery visual identification and single-cell retrieval of circulating tumor cells for genomic analysis using a dual-technology platform integrated with automated immunofluorescence staining

Study protocol

The efficacy and safety of irreversible electroporation for the ablation of renal masses: a prospective, human, in-vivo study protocol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits